Motor Neurone Disease Trial, Recruiting NCT07334743 Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Motor Neurone Disease Trial, Recruiting

NCT07334743
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people being evaluated for ALS:

  • You are 18 years old or older
  • Your doctor suspects you may have ALS (amyotrophic lateral sclerosis) but it has not necessarily been confirmed yet
  • You are already scheduled to stay at the HFAR neurology department for a standard set of diagnostic tests as part of your normal care (such as nerve tests, brain scans, spinal fluid tests, and blood tests)
  • You are willing and able to sign a written consent form to take part in the study
  • You are covered by a social security or health insurance system

For healthy volunteers (comparison group):

  • You are 18 years old or older
  • You are willing and able to sign a written consent form to take part in the study
  • You are covered by a social security or health insurance system

Who may not be able to join:

For people being evaluated for ALS:

  • You are under legal guardianship or a court-appointed protection order
  • You are currently pregnant or breastfeeding
  • You have had an active infection in the 4 weeks before the study blood or fluid samples are taken
  • You are currently being diagnosed with or treated for cancer
  • Your ALS diagnosis is ultimately not confirmed after testing (this would mean leaving the study at that point)

For healthy volunteers:

  • You are under legal guardianship or a court-appointed protection order
  • You are currently pregnant or breastfeeding
  • You have been diagnosed with a neurological disease
  • You feel you have memory or thinking difficulties (confirm with trial site)
  • You have had an active infection in the 4 weeks before the study samples are taken
  • You are currently being diagnosed with or treated for cancer

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Registry
ClinicalTrials.gov
Start date
17 September 2025
Est. completion
1 September 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Identification by RNA-seq of biomarkers carried by neuron-derived extracellular vesicles (NVEC) present in the blood of ALS patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov